(March 24 19:30) Forbes.com
We believe that Inovio Pharmaceuticals , a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14...
You can find the original article
here